We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > 4-1BB

News List

Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin L prnasia
July 22, 2021
Antengene announced that the Bellberry Human Research Ethics Committee (HREC) in Australia has approved the clinical trial application of the phase 1 trial of ATG-101 in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma.
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio prnasia
July 02, 2021
I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced multiple advancements in its 4-1BB bispecific antibody portfolio.